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Abstract 
 
Pathological remodelling, degeneration and reactivity of astrocytes are fundamental 
astrogliopathies contributing to all neurological diseases. In neurodegenerative 
disorders (including Alzheimer's disease, AD) astroglia undergo complex changes 
that range from atrophy with loss of function to accumulation of reactive cells around 
disease-specific lesions (senile plaques in the case of AD). The cellular pathology of 
astroglia in the context of human AD remains enigmatic; mainly because of severe 
limitations of animal models, which, although reproducing some pathological features 
of the disease, do not mimic its progression in full. Human induced pluripotent stem 
cells technology creates a novel and potentially revolutionising platform for studying 
fundamental mechanisms of the disease and for screening to identify new therapeutic 
compounds. 
 
Key words: Alzheimer’s disease; astrocyte; astroglial atrophy; induced pluripotent 
stem cells; glutamate transporter EAAT1, GFAP, protein S100B, astrogliopathology 
 3 
 
Astroglia: Homeostatic and defensive cells of the CNS 
 
Astrocytes (or star-like cells [1]) are a highly heterogeneous class of 
neural cells residing in the brain and spinal cord. Astrocytes are the major homeostatic 
cells of the CNS, executing their diverse functions at molecular, cellular, tissue and 
organ levels; furthermore astrocytes contribute to several systemic functions such as 
regulation of Na+ balance, energy homoeostasis and food intake [2-5]. Multiple 
homoeostatic pathways expressed in astroglial cells represented, for example, by 
membrane transporters for neurotransmitters [6], a complex system of secretion of 
neuromodultors, neurotransmitter precursors and hormones [7] or aerobic glycolysis 
producing energy substrates [8] maintain CNS functional activity and provide 
essential neuroprotection.  
 
Astrocytes are integrated into functional syncytia by gap junctions formed by 
connexions Cx43 and Cx36 and these gap junctional channels, or connexons, are 
permeable to hydrophilic molecules with molecular weight < 1 kDa thus allowing 
intercellular transfer of ions, second messengers, nucleotides, glutathione, 
prostaglandins, metabolites, vitamins and RNA [9]. Astroglial syncytial networks are 
segregated within defined anatomical structures; for example, astroglial syncytia are 
limited to individual barrels in the somatosensory cortex [10]. Astrocytes establish 
heterocellular contacts with oligodendrocytes, which are likely important for ion 
homoeostasis in the white matter [11]. Thus astrocytes represent the "reticular" 
portion of the CNS and can provide for functional integration of neuronal ensembles 
and synaptic fields. In the grey matter astrocytes occupy non-overlapping territorial 
domains, therefore dividing the nervous tissue into relatively independent glio-neuro-
vascular units that bridge neurons with vasculature and regulate functional hyperemia 
[12]. Astroglial endfeet plaster capillaries and form perivascular space that is a key 
element of the CNS-wide glymphatic system that removes excreted proteins and toxic 
molecules from the interstitium by the virtue of convectional fluid flow [13, 14].  
 
Within their territorial domains astroglial membranes cover neuronal elements. In 
particular perisynaptic astroglial processes enwrap the majority of excitatory synapses 
in the brain, forming the ‘astroglial cradle’ critical for synaptogenesis, synaptic 
maturation, synaptic maintenance and extinction [15]. Astrocytes control 
neurotransmitter dynamics in the CNS through neurotransmitter removal and 
subsequent catabolism. Astrocytes, for example, specifically express adenosine 
kinase, which is the key enzyme for adenosine degradation [16] and 
monoaninoxidase-B, which the major enzyme of catabolism of catecholamines [17]. 
Astroglial cells are a central element of glutamate/GABA-glutamine shuttle that 
supplies neurones with glutamine, an indispensable precursor of glutamate and 
GABA. Operation of this shuttle is supported by astrocyte plasmalemmal expression 
of transporters for glutamate, GABA and glutamine, and by the astroglia-specific 
enzyme glutamine synthetase [18].  
 
The defensive capabilities of astroglia are defined by their homeostatic pathways and 
by their evolutionary conserved defence response, known as reactive astrogliosis. 
Astrocytes protect neurones through glutamate clearance and K+ buffering (which 
curtail excitotoxicity), through supplying neurones with energy substrates or through 
provision of reactive oxygen species scavengers [19]. Insults to the CNS (of various 
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aetiology and acuteness) trigger a complex remodelling of astrocytes, which results in 
multiple "reactive" phenotypes that can be neuroprotective as well as neurotoxic [20-
23]. Furthermore, astroglial reactivity is, most likely, context and disease-specific, 
which further increases the number of possible reactive phenotypes [24]. Although, at 
its very core, reactive astrogliosis is a defensive response, it may acquire (for example 
during chronic or excessive activation) mal-adaptive dimensions [24, 25]. 
 
Specific properties of human astroglia 
 
The evolution of astroglia arguably reaches its summit in the brain of humans and 
higher primates [5]. The protoplasmic and fibrous astrocytes of the human brain are 
substantially (10 - 20 times) larger and protoplasmic astrocytes are substantially more 
complex than the astrocytes of rodents. As a result, a human protoplasmic astroglial 
cell covers ~ 20 times more synapses than the same cell in the rodent brain [26, 27]. 
In addition, human brains contain several unique types of astrocytes, which are absent 
in non-primate CNS and which extend one or more exceptionally long processes, in 
the order of millimetres. A rather abundant type of human astroglia (which may 
account for ~ 10% of all astroglial cells in the human brain) is represented by 
interlaminar astrocytes, discovered at the end of 19th century [28, 29]. These cells 
have relatively small bodies (~10 m) localised to cortical layer I, several short and 
one or two millimetre-long processes, which penetrate through layers II to IV and 
terminate with characteristic bouton-like structures known as terminal masses or end 
bulbs [26, 29]. A second type of astroglia, found only in humans and higher primates 
are polarised astrocytes. Somata of these astrocytes are positioned in the deep cortical 
layers close to the white matter; these cells send two exceptionally long (1 to 5 mm in 
length) processes that penetrate into superficial cortical layers [26]. Finally, human 
brains have a peculiar astrocyte subset, generally similar to protoplasmic astroglia 
with several very long (up to 1 mm) unbranched processes with evenly spaced 
varicosities that extend in all directions throughout the cortex, many of which are in 
contact with blood vessels [26, 30]. These astrocytes never appear in the brains of 
neonates, and the density of these astrocytes varies substantially between individuals 
[30]. 
 
Beyond morphological differences, further heterogeneity is revealed by the relative 
protein expression profiles human astroglia. Whilst all of the human astroglial 
subtypes outlined above are positive for canonical astrocyte marker, glial fibrillary 
acidic protein (GFAP), their expression of other astrocyte-associated proteins such as 
the calcium binding protein, S100B, excitatory amino acid transporters 1 and 2 
(EAAT1/2) and glutamine synthetase vary markedly [26, 30]. Indeed, interlaminar 
astrocytes, as well as varicose projection astrocytes for example, are unique in their 
reactivity to antibodies against the extracellular matrix receptor, CD44 [31, Sosunov, 
2014 #29] 
 
Is there a possible link between specific morphology of human astrocytes and 
cognitive superiority of the human brain? Recent experiments have demonstrated that 
grafting of foetal human glial progenitor cells (hGPCs) into the brains of young 
immunosuppressed mice resulted in a substantial change in neural networking. 
Astrocytes derived from these progenitors-derived astrocytes readily expanded and 
populated large portions of the mouse brain, subsequently replacing host astroglia yet 
retaining their human-specific morphology and complexity [32, 33,Goldman, 2015 
 5 
#95]. This "humanised" rodent brain demonstrated higher cognitive abilities as 
measured by improved memory, novel object recognition and auditory fear 
conditioning compared to wild type controls [32], further highlighting the enhanced 
capabilities of human astroglia comparative to rodent. Nonetheless, the underlying 
mechanisms for cognitive improvement remain to be discovered: these may indeed be 
associated with higher integrative capabilities of human astrocytes or reflect higher 
homeostatic capacity of the latter. 
 
Principles of astrogliopathology 
 
Diseases of the CNS can be generally defined as a homeostatic failure of nerve tissue, 
and hence they are directly associated with the functional performance of homeostatic 
neuroglia. Astrocyte pathology contributes to all types of neurological disorders. This 
contribution is complex and disease-specific; moreover, different astrogliopathic 
changes may develop simultaneously or sequentially during pathological evolution of 
neurological disorders. Conceptually, pathological changes of astroglia can be 
classified into astrodegeneration and asthenia with loss of function, pathological 
remodelling of astroglia and reactive astroglial response [19, 24, 25, 34]. 
Astrodegeneration and loss of function dominate, for example in neuropsychiatric 
disorders [35], astroglial pathological remodelling is predominant in Alexander 
disease or in some forms of epilepsy [36, 37], whereas astroglial reactivity assumes 
the leading role in neurotrauma and stroke [21, 38]. 
 
Astrocytes in Alzheimer's disease 
 
Neurodegenerative disorders reflect chronic extinction of neural tissue, which results 
in specific lesions and symptoms, such as impaired locomotive control in Parkinson's 
disease, or loss of motor neurones in amyotrophic lateral sclerosis and in more 
generalised cognitive downfall that ultimately terminates in dementia. The role for 
neuroglia in these diseases is yet to be fully understood. Notwithstanding, glial 
contribution to neuropathophysiology is receiving growing attention and the notion 
that the progression of neurodegenerative processes is defined, to a large extent, by 
the capability of glia to resist pathology and to compensate for functional failures 
gains wider acceptance [34, 39-45]. 
 
In Alzheimer's disease (AD), astroglia undergo complex and regionally-specific 
pathological changes. A decrease in astroglial profiles (indicative of atrophic changes) 
at the early stages of disease progression have been observed in studies on transgenic 
animals harbouring AD-related mutant human genes [46-50]. This coincided with 
suppressed astrogliosis in entorhinal and prefrontal cortices that may underlie high 
vulnerability of these regions to AD pathology [45, 48, 50]. At the later stages of 
disease, emergence of senile plaques elicited astroglial reactivity, with hypertrophic 
cells accumulating around the plaques [49, 51]. In the human brain, astrogliosis is 
prominent at the early stages of the disease, but decreases in advanced stages of AD, 
when overall glial paralysis contributes to severe brain atrophy [45, 52]. In summary, 
various aspects of astrogliopathic changes contribute to the progression of AD, and 
conceivably astrocytes define both early cognitive deficits due to deficient synaptic 
support while astroglial reactivity defines resilience of nervous tissue to the 
pathology. 
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Limitations of current models: The need for humanising astroglial research  
 
Progress in understanding AD has been hindered by the lack of suitable disease 
models [53, 54], reflected in an inability to translate results from animal studies to 
successful human therapies. The human pathology is dominated by the late-onset or 
sporadic form of AD (SAD); which disease variant does not display significant 
Mendelian genetic bias. AT the same time absolute majority of cell- and animal-based 
models of AD employ mutant genes isolated from the clinically rare, dominantly 
inherited familial AD (FAD) characterised by the early onset. Neuronal loss and 
cognitive deficits, which are the hallmarks of AD in humans, are rather limited in 
animal models [55]. Very little is known about pathological astroglial phenotypes in 
the context of human AD, again mainly because of limitations of animal models; in 
particular remarkable differences  between rodent and human astrocytes, hinder in 
depth characterisation of translational pathophysiology of human astroglia. 
 
Another significant barrier to studying human astrocytes is the difficulty of accessing 
and culturing sufficient astrocytes from the mature human brain. The current state-of-
the-art involves isolation of a proliferative progenitor cell that can be subsequently 
matured in vitro. However, these cells can quickly become quiescent in long-term 
cultures and when cultured in the presence of serum, show a morphological 
phenotype markedly different to those in vivo. A more recently developed technique 
known as ‘immunopanning’ provides improved isolation and purification of mature 
human astrocytes [56]. The ‘immunopanned’ cells were used to assess gene 
expression signatures in human and mouse astrocytes showing that only a third of the 
genes most enriched in human astrocytes were similarly expressed in mouse [56]. Of 
further significance, is that the authors also demonstrated functional hominid 
distinctions to rodents highlighted by differences in astroglial responses to exogenous 
glutamate.  Nonetheless, these types of invasive methods for human adult astrocyte 
sample collection remain challenging. Traditional cell-based approaches utilise assays 
based on primary cells and/or transformed cell lines, which fail to offer a 
physiologically relevant in vitro model that captures the specific genomic information 
of the patient or the biology for complex diseases of ageing with environmental and 
genetic risk factors, such as AD. Together, these limitations underscore a pressing 
need for new technologies that can replicate human (patho)physiology to provide 
means for improved disease modelling and a better understanding of human astrocyte 
development. 
 
A New Platform for Human Astrocyte Research and Drug Discovery 
 
Human induced pluripotent stem cells (iPSCs) are generated via reprogramming 
somatic cells with a number of key transcription factors that are crucial to maintaining 
undifferentiated embryonic stem cells (also termed pluripotent stem cells) [57-59]. 
This creates an ideal physiologically-relevant model because cells (i) can be derived 
from any individual; (ii) are genetically identical to the donor; (iii) can self-renew 
indefinitely and (iv) have the capacity to form any cell type of the body. Therefore 
providing a platform that offers significant advantages over existing models, by 
delivering the only source of clinically relevant, healthy and diseased human cell 
types amenable to various regenerative medicine applications (Fig. 1). 
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The continued progress of iPSC technology over the last decade has provided 
improved biologically relevant models, yet there are still considerable hurdles to 
overcome. Of particular relevance is the need for robust and cost-effective methods 
for the differentiation of iPSCs into mature major cell types of the CNS (such as 
neurones or astrocytes). Recent studies have shown that neurones differentiated from 
SAD- and FAD-iPSCs resemble pathologically affected cells in vivo and express key 
disease hallmarks [60-62], However, there is still a significant demand for tools that 
provide robust, homogeneous astroglial populations to help reveal astroglial 
contribution to neurodegenerative diseases. Despite a plethora of publications 
indicating the generation and utility of iPSC-derived neurones for disease modelling 
to date, in comparison only a limited number of studies have described consistent 
generation of enriched astrocytes from healthy donors [63-68]. Generation of 
functional astroglia from healthy iPSCs has previously been reported to be time-
consuming (60 - 90 days post differentiation) with further limitations in purity 
(cultures show 20 - 30% contamination with unwanted cell types) [63-65, 69], which 
denotes a significant challenge in delineating autonomous contribution of astroglia in 
disease pathogenesis. Current protocols exploit the gliogenic switch observed during 
embryonic development in vivo, whereby human iPSC-derived astroglia can be 
derived from either patterned neural stem cells (NSCs) or from committed glial 
lineage precursors that represent an intermediate population of progenitors [70, 71]. 
This directed differentiation relies on the activation of a number of key signal 
transduction pathways that contribute to astroglial differentiation, proliferation and 
maturation at specific time points. We have recently demonstrated [72] highly 
efficient generation of enriched populations of mature human cortical astroglia (with 
less than 5% of neurone contamination) from independent donor iPSC lines, within 30 
days of induction from cortical NSCs. This technique adapted a chemically-defined 
differentiation protocol [63] in which NSCs were exposed to ciliary neurotrophic 
factor (CNTF), which is known to induce astrocyte formation in cerebral cortical 
precursors by activation of downstream JAK/STAT signalling that transcriptionally 
activate astrocyte specific loci, such as GFAP and S100B[73]; and bone 
morphogenetic protein 2 (BMP2), which has also been shown to drive astrocyte 
differentiation from NSCs [74, 75]. In order to augment astrocyte formation, the 
media was supplemented with exogenous mitogens, epidermal growth factor (EGF) 
and insulin, which have been shown to increase glial commitment, primary astrocyte 
proliferation and sub-culturing in vitro [76, 77]. A principal schematic diagram of 
astroglial differentiation from human iPSCs is presented in Fig. 2 A - C.  
 
Astrocytes derived from human iPSCs exhibit typical morphology associated with 
primary astroglial cells in vitro and express several archetypal markers (Fig. 2C). 
Moreover, healthy iPSC-derived astroglia show significant morphological 
heterogeneity, arguably reflecting well-characterised astroglial heterogeneity in vivo 
[26, 30, 78, 79]. The iPSC-derived astrocyte populations showed robust expression of 
GFAP, a classical marker of astrogliosis that is always up-regulated in vitro [80]. 
Similarly, iPSC-derived astroglia have been found to express other canonical markers, 
such as CD44 antigen, S100B or aldehyde dehydrogenase1 family member L1, 
ALDH1L1 and several astroglia-specific molecules critical for astroglial homeostatic 
function, such as, glutamate transporter EAAT1 and EAAT2 and glutamine 
synthetase [71, 72]. Additional functional studies have shown that iPSC-derived 
astroglia derived from human iPSCs are capable of generating spontaneous Ca2+ 
signals [71, 81], have phagocytic activity and mount neuroimmunological response 
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[81], although detailed physiological characterisation of these cells is yet to be 
produced. Of further interest is the characterisation of astroglial regional subtypes 
throughout the CNS. While this is limited by incomplete knowledge of robust markers 
to delineate such cells, there is some evidence to suggest that maturation of neurones 
or glia from regionally specified iPSC-derived NPCs maintain their regional identity 
[82]. Together these data validate the use of iPSC models for interrogation of human 
astroglial function and development, which to date, is still largely unknown.  
 
Patient iPSC-derived astroglia exhibit AD-related pathological signatures 
 
Astroglia contribute to non-cell autonomous mechanisms in various 
neurodegenerative disorders that were classically considered exclusively neuronal 
diseases [34, 83]. Although studies of cell-autonomous pathobiology of human 
astrocytes derived from patient stem cells are in the nascent state, several lines of 
evidence show that these astroglia retain some pathological disease signatures, 
including in AD (Table 1).  
 
Human astroglia reprogrammed from dermal fibroblasts of a 53 year old male donor 
with type III early onset FAD (bearing an M146L mutation in the presenellin-1 gene, 
PSEN1) and from an 87 year old female clinically affected with late-onset SAD 
(homozygous for the 4 allele of apolipoprotein E, ApoE4+/+; the single-largest genetic 
factor determining SAD risk) exhibited morpho-pathological phenotypes when 
compared with iPSC-derived astroglia reprogrammed from a healthy control [72]. 
This pathological signature comprised of (i) mislocalisation and abnormal expression 
of mature astrocyte markers, (ii) compromised astrocyte heterogeneity and (iii) 
astroglial atrophy. Astrocytic dysgenesis, manifested as an almost complete loss of 
processes and overall reduction in cell size was significant (Fig. 3); this finding 
strongly correlates with observations of morphological astroglial atrophy in early 
stage AD pathology in mouse models [45, 49]. In contrast, astrocytes derived from 
iPSCs isolated from patients with fronto-temporal dementia show hypertrophic 
morphology [69] further indicating disease-specific glial metamorphoses. 
 
Distribution of astroglial markers was similarly aberrant in cells derived from AD 
patients. For example, S100B in AD iPSC-derived astroglia was almost entirely 
confined to large nuclear inclusions, in contrast to healthy iPSC-derived astroglia, 
which show typical cytoplasmic localisation. This was accompanied by significant 
decrease in total S100B expression in AD-astroglia when compared to control 
astroglia. Since S100B is known to interact with various cytoskeletal components, this 
phenomenon may represent a novel and early mechanism underlying SAD- and FAD-
induced astrocytic atrophy. Mislocalisation was also observed for glutamine 
synthetase in both FAD and SAD- astroglia, while the glutamate transporter EAAT1 
was misplaced only in SAD iPSC-derived astroglia. Furthermore, the expression 
levels of both EAAT1 and glutamine synthetase were decreased only in FAD-derived 
astroglia [72]. A recent study using iPSC-derived astrocytes from donors with PSEN1 
Δ9 mutation failed to show differences in expression of S100B, EAAT-1 and -2 
transcripts compared to healthy donors [84]. However, these differences can be 
attributed to the fact that protein mislocalisation and discrete changes in protein levels 
might not be captured at the transcript level. Intriguingly, other iPSC-based studies 
have shown that astroglia derived from iPSCs from SAD and FAD backgrounds as 
well as from healthy individuals carrying APOE4, exhibit no significant deficit in 
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their overall abilities to sequester extracellular glutamate compared to controls [66, 
85]. Whether these findings are a result of the application of glutamate assay 
concentrations being orders of magnitude higher than predicted physiological levels 
[86], and hence masking nuanced alterations in uptake, or whether they imply that it is 
the processing rather than gross uptake of glutamate that is altered in AD, remains to 
be established. Astrocytes derived from iPSCs obtained from AD patients with 
PSEN1 E9 mutation demonstrated aberrant Ca2+ signaling and altered release of 
cytokines [84].  
 
Accumulation of -amyloid oligomers in intracellular organelles has been described 
in some, but not in all, iPSC-derived SAD- and FAD- astrocytes, concomitant with 
the induction of both ER and oxidative stress [66]. Specifically, those astrocytes 
derived from patients with the APP-E693 mutation demonstrated large inclusions of 
-amyloid, which were shown to co-localise to the endoplasmic reticulum, early 
endosomes and lysosomes, while those from APP-V717L patients showed no 
accumulation at all. Increased astroglial -amyloid production was also observed in 
astrocytes derived from patients with PSEN1 E9 mutation [84]. These findings shed 
new insight into disease heterogeneity, both within and between SAD and FAD, and 
are supportive of our own findings of subtle variations at the cellular level between 
the two forms of the disease [72]. At the same time, production of -amyloid as well 
as soluble amyloid precursor protein- was detected in astrocytes derived from 
healthy human iPSCs, possibly hinting on the role of astroglia in amyloidogenesis 
[67].  
 
Out of three human isoforms of apolipoprotein homozygous expression of the E4 
alleles confers significantly increased risk for late-onset SAD [87]. In contrast, the E2 
isoform has been reported to confer a protective mechanism against AD; and the most 
common, E3 isoform appears pathologically neutral [88]. While it is known that 
ApoE contributes to neuronal health by transporting the cholesterol required for 
cellular repair, synaptic plasticity and dendritic spine integrity [89], the precise 
mechanisms by which the ApoE isoforms contribute to AD pathogenesis or protection 
are not fully understood. Astroglia generated from iPSCs derived from ApoE4 +/+ 
donors secrete active ApoE, but exhibited profound hypolipidation in astrocytes 
ApoE4+/+ SAD-prone background compared to ApoE3+/+ controls (Zhao, 2017 #90, 
consistent with findings in mice and humans [90, 91]. Thus, human iPSC-derived 
astrocyte models provide an excellent platform to study relative contribution of its 
isoforms to AD progression.  
 
Of further interest is that iPSC-derived ApoE4+/+ astrocytes show impaired abilities to 
support neuronal survival and synaptogenesis, compared to healthy iPSC-derived 
astrocytes; indicating a loss of neurotrophic and neuroprotective functions [85]. This 
functional deficit appears independent of neuronal contact or glutamate scavenging, 
hence implicating alterations in the astrocytic secretome. Indeed, we revealed 
significant alteration of the constitutive secretion of the pro-inflammatory mediators 
IL-8 (CXCL8) and MCP-1 (CCL2) in FAD- and SAD iPSC-derived astroglia when 
compared to healthy iPSC-derived astroglia [72]. These observations may further 
indicate a potential glial paralysis that has been postulated to be a fundamental factor 
in the evolution of AD [45]. In summary, astroglia derived from iPSCs are capable of 
mimicking in vitro a wide variety of deficits in homeostatic molecular cascades 
 10 
intimately associated with AD that are routinely observed in vivo and in patients [92-
95]. 
 
Harnessing iPSC technology will also provide a novel platform for accelerated drug 
discovery. Recent proof of concept studies have demonstrated iPSC-derived 
astrocytes as a promising cellular tool for high throughput compound screening [96] 
and for personalised treatment across a number of neurological disorders [66, 97, 98]. 
By testing whether drugs have differential effects in iPSC-derived astrocytes, we can 
begin to unravel how genetic variation and/or cellular phenotypes in AD can dictate 
responses to different drugs and help to elucidate novel targets.  
 
Conclusions  
 
Human astrocytes bear numerous idiosyncratic features that fundamentally distinguish 
them from astroglia in lesser mammals. Astroglia are a fundamental component to 
neurodegenerative diseases; hence studies of human astrocytes are of significant 
importance for further understanding of the mechanisms of neurodegeneration. The 
intent of this review was to broadly summarise recent progress in iPSC technology to 
develop novel cellular platforms for studying human astrocytes in the context of AD. 
Astroglia can be readily derived from somatic cells of patients suffering from AD; 
these cells express canonical astroglial markers and bear a number of pathological 
signatures. Further characterisation of the functional pathological phenotype of these 
cells is of ultimate importance for establishing a new human-based platform that will 
provide us with a better understanding of early changes in CNS homeostasis leading 
to AD that can be used in high throughput phenotypic screening assays to identify 
potential new therapeutic compounds that may provide a better clinical outcome for 
patients. 
 
 
Future perspectives 
 
"Humanisation" of neuropathological research is the main challenge which theoretical 
medicine is facing. A large majority of neurological diseases do not have an effective 
cure and with only symptomatic therapies available at best. There are classes of 
neurological disorders (most notably neuropsychiatric, neurodevelopmental and 
neurodgenerative  diseases) which do not develop in animals (rare occurances of 
neurodegenrative phenotype in lemurs or in some canines remain exeptions), and 
hence require development of artificial animal models. These are commonly produced 
in model organisms such as mice, zebrafish and Drosophila due to their  amenability 
for genetic manipulation. However, the brains of these animals are not even remotely 
close to the brain of humans, their lifespan is significantly shorter and thir social 
inetractions are much inferior and fundamentally distinct to humans. These limitations 
undrlie slow progress of neurological therapies.   
 
Another salient revolution developing over last decade concerns a fundamental shift 
in the understanding of cellular pathophysiology of the brain. The classical paradigm 
that regards neurones as the cell-autonomous substrate of neuropathology has shifted 
towards neuroglial mechanisms, that, by virtue of homeostatic and defensive 
capabilities, seem to determine the resitivity of nervous tissue to pathological insults 
and chronic neuropathologies. Evolution of astroglia from lesser mammals to humans 
 11 
is remarkable and human astroglia are unique in their complexity compared to 
rodents. Poor translation from animal models to clinical outcomes has severely 
limited the development of effective therapeutics for neurological disorders to date, 
not least AD which remains incurable. The idiosyncratic astroglia of the human brain 
might be the key to better understanding of uniquely human neurological diseases; 
hence the development of such human-based models as described here to more 
accurately study such diseases is essential. Emerging evidence using iPSC astroglial 
models is beginning to uncover subtle variations in individual molecular and cellular 
phenotypes not only between but also within FAD and SAD classifications. Invariably 
these models pave the way towards the stratification of patient treatment regimes and 
personalised medicine.  
 
However, as a note to the reader, it should be emphasised that cultured astrocytes 
represent a simplified model relative to that of astrocytes in the CNS, whereby 
additional interactions with other cell types and matrix components are likely to 
influence the astrocytic phenotype.  Yet, highly purified human astrocyte cultures 
combined with recent advances in precision genome editing such as CRISPR/Cas9 
represent a unique system to delineate the autonomic responses of astrocytes to 
defined stimuli/matrix/co-cultures in both healthy and AD-affected cells in an 
unparalleled manner.  
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Executive summary 
 
 Astrocytes are a class of neuroglia primarily responsible for overall 
homeostasis of the nervous system. 
 Astrocytes are now understood as key elements of virtually all neurological 
diseases and thus represent an understudied target for therapy development. 
 
Limitations of current models for studying astrocytes 
 
 Human astrocytes differ significantly from rodent counterparts, exhibiting 
complex heterogeneity and comprising multiple unique subtypes exclusive to 
the higher primates brain 
 Studies performed using either wild-type or transgenic rodent astrocytes have 
inherently limited translational value for understanding the nuances of 
astrocytic roles in human disease. 
 Opportunities for accessing and culturing mature human astrocytes are 
extremely limited. 
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Human induced pluripotent stem cells 
 Human induced pluripotent stem cells (iPSCs) are created by reprogramming 
adult somatic cells to a nascent stem-like state. 
 iPSCs maintain the capacity to differentiate in vitro to all cell types of the 
body by exposing them to defined combinations of growth factors, cytokines, 
hormones and mitogens. 
 
A new platform for studying astrocyte biology 
 A number of studies have described directed differentiation of iPSCs to 
astrocytes in vitro. 
 Recent technological advances have improved robustness, reduced timelines 
for astrocyte maturation and minimised contamination by unwanted cells such 
as neurones. 
 Human iPSC-derived astrocytes exhibit typical astroglial morphology and 
heterogeneity, express mature astrocyte markers and perform a number of key 
astrocytic functions, validating them as models for the investigation of human 
astroglial function and development. 
 
iPSC-derived astrocytes as a model for studying pathophysiology 
 
 iPSCs are derived from somatic cells (e.g. skin fibroblasts) of patients with 
various pathologies and can subsequently be differentiated into astrocytes. 
 Recent studies have demonstrated the derivation of astrocytes from AD patient 
iPSCs. 
 AD patient iPSC-derived astrocytes display key features of disease phenotype, 
including morphological aberrance, cellular stress, loss of neurotrophic and 
neuroprotective functions, alterations in the secretome and impaired lipidation 
status. 
 Notably, these cells retain the patient’s own unaltered genome and express 
disease-associated genes at physiological levels, making them an excellent 
platform for investigating disease and testing new therapies. 
 
Conclusion 
 
 Patient iPSC-derived astrocytes represent an unrivalled model for the 
investigation of human astrocyte development, astrocyte pathophysiology in 
AD and for screening to identify new therapeutic compounds. 
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Tables 
 
Table 1. Pathological signatures of iPSC-derived astrocytes obtained from donors 
with AD. 
 
AD form 
 
Pathological signature Reference 
FAD  
PSEN1E9 mutation 
  
iPSC-derived AD astrocytes 
have aberrant Ca2+ signalling, 
altered cytokine secretion, 
increased production of reactive 
oxygen species and decreased 
production of lactate. 
[84] 
Clinically healthy 
individuals carrying 
APOE4 alleles 
APOE4 iPSC-derived astrocytes 
have reduced supportive and 
neurotrophic functions. 
[85] 
FAD 
APP-E693Δ) and APP-
V717L) mutations 
SAD 
iPSC-derived  AD astrocytes 
showed -amyloid intracellular 
accumulations. AD astrocytes 
also demonstrated signs of ER 
stress and increased levels of 
reactive oxygen species.  
[66] 
FAD (PSEN1 M146L 
mutation) 
SAD (homozygous 
APOE4 alleles) 
iPSC-derived  AD astrocytes 
have atrophic morphology as 
well as aberrant expression and 
localisation of glutamate 
transporter EAAT1, glutamate 
synthetase and S100B protein. 
AD astrocytes also had 
decreased constitutive secretion 
of soluble inflammatory 
mediators. 
[72] 
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Figure legends 
 
Figure 1.  Principles of stem cell technology  
 
Human induced pluripotent stem cells (iPSCs), non-invasively generated from 
somatic cells (e.g. skin fibroblasts), have the capacity to self-renew indefinitely, can 
generate all cells of the body and retain the genetic information of the donor. Robust 
generation of specific mature neural cells (such as astroglia) from iPSCs created from 
patients with brain pathologies offer an unrivalled platform for the study of human 
brain disorders in vitro, including the screening of potential novel therapeutics, more 
accurate disease modelling and in cellular and personalised therapy. 
 
Figure 2. Schematic diagram showing astrocyte differentiation from human iPSCs. 
A: The differentiation of astrocytes from iPSC colonies follows the early neuronal 
developmental progress through adherent culture stages over 30 days (from left to 
right).  
 
B: An undifferenatiated iPSC colony immunostained for markers of pluripotency 
(Oct3/4 is shown in red and the cell surface marker TRA-180 in green). Initial 
directed differentiation of pluripotent iPSCs towards neural induction is triggered by 
serum induction and SMAD inhibition for 6-7 days.  
 
C: iPSC-derived neural stem cells (NSCs) form polarised rosettes expressing 
canonical markers such as nestin (shown here in green). Following NSC expansion 
for a further 6-7 days, glial progenitor formation is induced by the supplementation of 
EGF, BMP-2, CTNF and insulin.  
 
D: By day 14, glial commitment is achieved, and after 30 days astrocytes express 
classical markers of nature astroglial cells GFAP, protein S100B, glutamate 
transporter EAAT1 and glutamine synthetase GS. Immunostaining is shown in green, 
DAPI counterstained nuclei are shown in blue. Scale bars = 50 µm (Inset; 20 µm). 
Panel D is Reproduced from [72]. 
 
Figure 3. Comparison of healthy, FAD and SAD patient-derived -III-tubulin 
immunoreactive neurones and GFAP immunoreactive astrocytes.  
 
Under terminal neuronal differentiation conditions for 35-40 days, all patient samples 
showed positive expression of the neural marker -III-tubulin (green) no significant 
difference in the proportion of -III-tubulin+ neurones between any individual was 
observed (N = 4 per group, ANOVA, F (2,9) = 0.128, p = ns).  
 
In contrast, AD-astrocytes derived from identical patient NPCs show markedly 
reduced heterogeneity of morphology and striking atrophy compared to healthy cells 
(GFAP; green). These findings validate that atrophic astroglia do not arise as a result 
of defective neuronal intermediates in either form of AD, but as a cell-autonomous 
event. Scale bar = 50 μm, 
 
Reproduced from [72] 
 
